-Thomas J Kipps Researcher Activity Profile

Research Author Detailed Information 

Thomas J Kipps Publication Rate By Year

Thomas J Kipps has published 1 paper(s) in 2003, 2 paper(s) in 2006, 8 paper(s) in 2007, 5 paper(s) in 2008, for a total of 16 research publications in total.

Thomas J Tj Kipps Author Information

LAST NAME: kipps

FIRST NAME: Thomas J

INITIALS: tj

AFFILIATION:

Papers

Thomas J Kipps's Publication Record

1. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Year Published: 2006
Moores Cancer Center, University of California, San Diego, CA, USA. lrassenti@popmail.ucsd.edu
2. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Year Published: 2007
Division of Hematology/Oncology, Department of Medicine, UCSD School of Medicine, La Jolla, CA, USA. kakazu@sapmed.ac.jp
3. Cellular immune therapy for chronic lymphocytic leukemia. Year Published: 2007
Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. a.p.kater@amc.uva.nl
4. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Year Published: 2007
Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.
5. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Year Published: 2007
Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
6. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. Year Published: 2007
7. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Year Published: 2006
Moores Cancer Center, University of California, San Diego, CA, USA. lrassenti@popmail.ucsd.edu
8. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. Year Published: 2007
9. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Year Published: 2007
Division of Hematology/Oncology, Department of Medicine, UCSD School of Medicine, La Jolla, CA, USA. kakazu@sapmed.ac.jp
10. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Year Published: 2007
Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.
11. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Year Published: 2008
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA. atsimber@mdanderson.org
12. Biology and treatment of chronic lymphocytic leukemia. Year Published: 2003
University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA.
13. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Year Published: 2008
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA. atsimber@mdanderson.org
14. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Year Published: 2008
Moores UCSD Cancer Center, University of California-San Diego, 3855 Health Sciences Drive No. 0820, La Jolla, CA 92093, USA.
15. MiR-15a and miR-16-1 cluster functions in human leukemia. Year Published: 2008
Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210.
16. MiR-15a and miR-16-1 cluster functions in human leukemia. Year Published: 2008
Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA. gcalin@mdanderson.org